Ginkgo Bioworks IPO

Ginkgo Bioworks was founded in 2008 by Jason Kelly, Reshma Shetty, Barry Canton, Austin Che, and Tom Knight. The company has not officially endorsed a plan to participate in an IPO.

Ginkgo specializes in leveraging biological processes in organisms to meet the needs of their clients in industries ranging from cosmetics to food goods. Their website claims the firm’s expertise is in cultured ingredients, strain improvement, and enzymes. The company has raised nearly $800 million in Venture Capital funding from investors including Reshape Holdings, T. Rowe Price, Innovation Camp, Illumia, Power Gate Ventures, Alrai Capital, OS Fund, Azure Capital Partners, Data Collective, Felicis Ventures, Vast Ventures, and Y Combinator. Per company press releases, Ginko last raised a Series E expansion in May 2020 bringing the round total to $360 million at a post-money valuation of nearly $5 billion.

Total Funding to Date$785.53MM
Register for Details

For more details on financing and valuation for Ginkgo Bioworks, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Ginkgo Bioworks Ticker Symbol


Ginkgo Bioworks Stock Price

$1.80 as of 12/5/22

Major Investors for Ginkgo Bioworks

General Atlantic
Y Combinator
Viking Global Investors
T. Rowe Price
Bill Gates

Ginkgo Bioworks Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/28/2020 Series E $360MM raised $XXX.XX $XXX.XX
12/14/2017 Series D $275MM raised $XXX.XX $XXX.XX
6/8/2016 Series C $98.9MM raised $XXX.XX $XXX.XX
7/8/2015 Series B $51.63MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data